卡培他滨联合顺铂对比替吉奥联合顺铂一线治疗晚期胃癌的随机II期试验
本研究为随机II期试验,比较卡培他滨联合顺铂(XP)与替吉奥联合顺铂(SP)一线治疗晚期胃癌的疗效与安全性。主要终点无进展生存期(PFS)在两组均高于方案预设的40%阈值,XP与SP疗效相当,均可作为III期研究的对照臂。组织学亚型未能区分XP或SP的优势人群。
要点
- XP与SP的24周PFS率分别为43.5%和50.9%,均超过40%阈值。
- 两组中位PFS、OS无显著差异,ORR在XP组显著更高(69.4% vs 42.4%)。
- XP与SP毒性谱略有不同,但均可作为晚期胃癌III期研究的对照方案。
核心结论
- XP与SP疗效相当,均可推荐作为晚期胃癌III期研究的对照臂。
- 组织学亚型不是选择XP或SP的敏感标志物。
研究设计与样本
- 随机II期试验,纳入110例符合条件的晚期胃癌患者。
- 患者随机接受SP(替吉奥40 mg/m2 21天+顺铂60 mg/m2,每5周)或XP(卡培他滨1000 mg/m2 14天+顺铂80 mg/m2,每3周)。
- 主要终点为无进展生存期(PFS),次要终点包括总生存期(OS)、总缓解率(ORR)和安全性。
主要发现
- 24周PFS率:SP组50.9%,XP组43.5%,均高于方案预设的40%阈值。
- 中位PFS:SP组5.6个月,XP组5.1个月(HR 1.126,p=0.5626)。
- 中位OS:SP组13.5个月,XP组12.6个月(HR 0.942,p=0.7769)。
- ORR:SP组42.4%,XP组69.4%(p=0.0237)。
- 最常见≥3级不良事件:SP/XP组贫血(16%/20%)、中性粒细胞减少(9%/18%)、厌食(18%/13%)。
关键数值与推荐
- 24周PFS率在SP组为50.9%、XP组为43.5%,均超过方案预设的40%阈值。
- 中位PFS在SP组为5.6个月、XP组为5.1个月(HR 1.126,p=0.5626)。
- 中位OS在SP组为13.5个月、XP组为12.6个月(HR 0.942,p=0.7769)。
- ORR在SP组为42.4%、XP组为69.4%(p=0.0237)。
临床怎么用
- XP和SP均可作为晚期胃癌一线治疗的合理选择,并可作为III期研究的对照方案。
- 组织学亚型不推荐用于选择XP或SP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Capecitabine plus cisplatin (XP) is a standard global regimen, while S-1 plus cisplatin (SP) is a Japanese standard for first-line treatment of advanced gastric cancer (AGC). We conducted a phase II trial comparing XP with SP for patients with AGC to confirm whether these regimens can be used as controls in a phase III study and to explore whether histological subtypes favour XP or SP. PATIENTS AND METHODS: Eligible patients were randomised to receive either S-1 40 mg/m2 for 21 days plus cisplatin 60 mg/m2 (q5w) or capecitabine 1000 mg/m2 for 14 days plus cisplatin 80 mg/m2 (q3w). The primary end-point was progression-free survival (PFS). The secondary end-points were overall survival (OS), overall response rate (ORR) and safety. RESULTS: In 110 eligible patients, 24-week PFS was higher in both groups (SP 50.9%, XP 43.5%) than the protocol-specified threshold of 40%. The median PFS for SP versus XP was 5.6 and 5.1 months (hazard ratio [HR], 1.126; p = 0.5626); OS was 13.5 and 12.6 months (HR, 0.942; p = 0.7769) and the ORR was 42.4% and 69.4% (p = 0.0237), respectively. The most common grade ≥3 adverse events with SP/XP were anaemia (16%/20%), neutropenia (9%/18%) and anorexia (18%/13%). Subgroup analysis by histological classification showed no statistical difference between treatments. CONCLUSIONS: XP and SP are comparable and can be recommended as control arms in a phase III study for AGC. Histological subtypes were not sensitive markers for the selection of XP or SP. CLINICAL TRIAL REGISTRATION: NCT00140624.
引用
- Nishikawa K, Tsuburaya A, Yoshikawa T, et al. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). Eur J Cancer. 2018. PMID: 30096702. doi:10.1016/j.ejca.2018.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。